Drugs / Recombinant Interferon Alfa-2b
Trials 16
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03599453 | Jan 2019 → Sep 2020 | triple-negative breast carcinoma | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT04081389 | Dec 2019 → May 2022 | breast carcinoma in situ, triple-negative breast carcinoma | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT00217542 | Jul 2005 → Jul 2008 | melanoma, renal cell carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00217373 | Jun 2005 → Jan 2013 | neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04379518 | Nov 2020 → Mar 2023 | COVID-19, cancer, hematopoietic and lymphoid cell neoplasm | Roswell Park Cancer Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 27 trials · 1 missed | ||||||
| Phase 2 | NCT04093323 | Nov 2024 → Apr 2025 | — | Roswell Park Cancer Institute | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT03899987 | Nov 2019 → Apr 2027 expected | prostate adenocarcinoma | Roswell Park Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03403634 | Apr 2018 → Dec 2020 | colorectal carcinoma, metastatic carcinoma | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT01708941 | Jan 2013 → Aug 2017 overdue | cutaneous melanoma | National Cancer Institute (NCI) | Active not recruiting | Missed primary |
| Phase 2 | NCT00539591 | May 2008 → Jun 2015 overdue | melanoma | St. Jude Children's Research Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01158534 | Mar 2006 → Sep 2010 | renal cell carcinoma | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00101114 | Sep 2004 → May 2006 | clear cell renal carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 33 trials · 1 missed | ||||||
| Phase 3 | NCT01274338 | Jun 2011 → Feb 2019 overdue | cutaneous melanoma | National Cancer Institute (NCI) | Active not recruiting | Mixed |
| Phase 3 | NCT00569127 | Dec 2007 → Jan 2015 overdue | colorectal neuroendocrine tumor G1, gastric neuroendocrine tumor G1 | National Cancer Institute (NCI) | Active not recruiting | Missed primary |
| Phase 3 | NCT00002556 | Jul 1994 → Jan 2006 | plasma cell myeloma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01460875 | Apr 2008 → Jan 2014 | cutaneous melanoma | William Carson | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT00498979 Background | May 2007 → May 2010 | melanoma | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00398450 Background | Feb 2006 → Apr 2010 | cutaneous melanoma | University of California, San Diego | Completed | No outcome recorded |
| Phase 3 | NCT02506153 Comparator | Nov 2015 → Sep 2023 overdue | cutaneous melanoma, mucosal melanoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant interferon alfa-2b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00539591 ↗ |
| Known as | IFN-α-2b | “Patients were randomly assigned to treatment with octreotide LAR 20 mg every 21 days with either bevacizumab 15 mg/kg every 21 days or 5 million units of IFN-α-2b three times per week.” PMID 28384065 ↗ Apr 2017 |
| Modality | Protein / enzyme biologic | “Biological: recombinant interferon alfa-2b” NCT00002556 ↗ |
| Route | Subcutaneous | “Given SC” NCT00002556 ↗ |